HomeCompareVNUE vs PFE

VNUE vs PFE: Dividend Comparison 2026

VNUE yields 13333.33% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VNUE wins by $944051876715324800.00M in total portfolio value
10 years
VNUE
VNUE
● Live price
13333.33%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$944051876715324800.00M
Annual income
$930,326,183,604,330,300,000,000.00
Full VNUE calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — VNUE vs PFE

📍 VNUE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVNUEPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VNUE + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VNUE pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VNUE
Annual income on $10K today (after 15% tax)
$1,133,333.33/yr
After 10yr DRIP, annual income (after tax)
$790,777,256,063,680,700,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, VNUE beats the other by $790,777,256,063,680,700,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VNUE + PFE for your $10,000?

VNUE: 50%PFE: 50%
100% PFE50/50100% VNUE
Portfolio after 10yr
$472025938357662400.00M
Annual income
$465,163,091,802,165,140,000,000.00/yr
Blended yield
98.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VNUE
No analyst data
Altman Z
-1856.1
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VNUE buys
0
PFE buys
0
No recent congressional trades found for VNUE or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVNUEPFE
Forward yield13333.33%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$944051876715324800.00M$49.6K
Annual income after 10y$930,326,183,604,330,300,000,000.00$26,258.71
Total dividends collected$943142383073684224.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VNUE vs PFE ($10,000, DRIP)

YearVNUE PortfolioVNUE Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,344,033$1,333,333.33$9,153$693.39+$1.33MVNUE
2$168,918,905$167,480,789.20$8,593$849.25+$168.91MVNUE
3$19,852,785,021$19,672,041,793.12$8,336$1,066.78+$19852.78MVNUE
4$2,182,013,981,744$2,160,771,501,770.83$8,437$1,384.80+$2182013.97MVNUE
5$224,287,824,199,531$221,953,069,239,064.90$9,013$1,875.40+$224287824.19MVNUE
6$21,561,870,489,323,890$21,321,882,517,430,390.00$10,306$2,680.72+$21561870489.31MVNUE
7$1,938,749,165,623,537,400$1,915,677,964,199,961,300.00$12,820$4,101.38+$1938749165623.52MVNUE
8$163,055,200,603,353,700,000$160,980,738,996,136,500,000.00$17,673$6,826.70+$163055200603353.69MVNUE
9$12,827,750,571,022,997,000,000$12,653,281,506,377,408,000,000.00$27,543$12,591.86+$12827750571022998.00MVNUE
10$944,051,876,715,324,800,000,000$930,326,183,604,330,300,000,000.00$49,560$26,258.71+$944051876715324800.00MVNUE

VNUE vs PFE: Complete Analysis 2026

VNUEStock

VNUE, Inc. operates as a music technology company. The company provides a suite of products and services that monetize and monitor music for artists, labels, performing rights organizations, radio stations, venues, restaurants, gyms, bars, and other businesses. It offers Set.fm/DiscLive Network, a digital live music distribution consumer app platform that allows users to download and purchase through their mobile devices; and provides physical collectible products that are recorded and sold at shows, as well as online through the company's partner DiscLive Network. The company also provides Soundstr, a music identification and rights management cloud platform that track and audit public performances of music; and offers collectible products, such as CDs, USB drives, and laminates. VNUE, Inc. was founded in 2013 and is based in New York, New York.

Full VNUE Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VNUE vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VNUE vs SCHDVNUE vs JEPIVNUE vs OVNUE vs KOVNUE vs MAINVNUE vs JNJVNUE vs MRKVNUE vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.